Genmab risk profile
23 Normal where most of the sector sits
Measured 21 October 2026 from GMAB's filed statements. Recomputed nightly.
23 (Normal), driven by Operating pressure at 47, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 24 | Normal | Stable | One-year price volatility — 35.8% |
| Operating pressure | 47 | Elevated | Worsening | Operating-margin drift — -9.6 percentage points |
| Cash conversion | 22 | Normal | Easing | Cash conversion — 1.23x |
| Leverage and coverage | 24 | Normal | Worsening | Net debt to EBITDA — 2.78x |
| Competitive position | 10 | Contained | Stable | Operating-margin gap against peers — +21.7 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.